文献速递关节外科创伤骨科

假体周围关节感染患者中利福平治疗启动与完成的情况如何

How Often Is Rifampin Therapy Initiated and Completed in Patients With Periprosthetic Joint Infections?
PubMed 文献 · Clin Orthop Relat Res · 2025-01-23

该研究基于单中心机构数据库回顾2013年1月至2023年4月因假体周围关节感染(PJI)行清创、抗生素及假体保留(DAIR)或一期翻修的患者935例,其中9%(87/935)符合美国感染病学会(IDSA)指南利福平使用指征。符合指征者中仅49%(43/87)启动利福平,启动者中19%(8/43)未完成计划6周疗程;未用药者中70%(31/44)病历未记录原因。

要点

  • 符合IDSA利福平指征的PJI患者中仅49%(43/87)启动利福平治疗。
  • 启动利福平者中19%(8/43)未完成计划6周疗程。
  • 未用药者中70%(31/44)病历未记录未用药原因。

核心结论

  • 在一家大型三级转诊学术中心,符合IDSA指征的葡萄球菌性PJI患者中仅约半数启动辅助利福平治疗,多数未用药者病历未记录原因。
  • 作者认为,鉴于辅助利福平治疗患者结局更优的证据,所有符合指征的患者均应启动该药,除非有明确禁忌证,且禁忌证应予以记录。
  • 作者建议未来研究进一步评估利福平治疗葡萄球菌性PJI的临床获益以及哪些药物相互作用(DDI)应被视为真正的治疗禁忌证,可通过前瞻性研究评估辅助利福平治疗后长期无感染生存情况,并对这些DDI的潜在临床风险进行分层。

研究设计与样本

  • 回顾性研究,利用机构数据库识别2013年1月至2023年4月因PJI行DAIR或翻修关节置换术的患者935例。
  • 以IDSA临床实践指南定义的葡萄球菌性PJI经DAIR或一期翻修治疗作为利福平明确使用指征,查阅电子病历计算未用药比例、未完成计划疗程比例及记录的原因。
  • 回顾性审查患者启动辅助利福平时正在使用的药物,评估是否存在DDI及其潜在严重程度。
  • 证据等级为IV级,治疗性研究。

主要发现

  • 935例因PJI行DAIR或翻修关节置换术的患者中,9%(87/935)符合IDSA指南利福平使用指征。
  • 符合IDSA指征的87例中,49%(43/87)启动利福平。
  • 启动利福平的43例中,19%(8/43)在计划6周疗程完成前停药。
  • 未用药的44例中,70%(31/44)病历未记录原因;有记录的13例中,DDI为8例、担心肝毒性为1例、有副作用史为1例、其他原因为3例。
  • 提前终止治疗的8例中,胃肠道问题为5例、急性肾损伤为1例、其他原因为2例。

关键数值与推荐

  • 利福平使用指征依据IDSA临床实践指南:葡萄球菌性PJI经DAIR或一期翻修治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rifampin therapy is indicated for the treatment of staphylococcal periprosthetic joint infection (PJI) in patients who have undergone debridement, antibiotics, and implant retention (DAIR) or one-stage revision as per the Infectious Diseases Society of America (IDSA) guideline. Given the well-established effectiveness of rifampin as adjunctive therapy in staphylococcal PJI, it is crucial to evaluate its utilization in practice and identify factors that contribute to its underuse or incomplete administration, as these deviations may undermine treatment efficacy and patient outcomes. QUESTIONS/PURPOSES: Among patients who met clear indications for rifampin use having undergone DAIR or one-stage revision for staphylococcal PJI, (1) what proportion of patients did not receive it? (2) What proportion of patients started it but did not complete the planned course? (3) Where documented in the medical record, what were the common reasons for not using it or prematurely discontinuing it, and in what percentage of the patients' charts was no reason given? (4) What proportion of patients were taking a medication that put them at risk for a drug-drug interaction (DDI)? METHODS: Using an institutional database, patients who underwent DAIR or revision arthroplasty for PJI from January 2013 to April 2023 were identified (n = 935). We defined clear indications for rifampin use as a patient diagnosed with staphylococcal PJI treated via DAIR or one-stage revision, as set forth by the clinical practice guidelines of the IDSA. Based on those indications, we surveyed patients' electronic medical records (EMRs) and calculated the proportion of patients who did not receive the drug in situations where it would have seemed appropriate that they receive it. We then determined the planned length of antibiotic management and calculated the proportion of patients whose planned courses of rifampin were not completed based on what was documented in each patient's chart. Next, we performed a review of the EMR and recorded qualitatively the reasons why patients either did not receive rifampin or why the planned course was not completed, as well as the percentage of patients whose medical records did not indicate why the drug was not used or was discontinued before the planned course had been administered. Last, we retrospectively reviewed the medications that the patients were taking at the time of indicated adjunctive rifampin initiation and evaluated whether there were DDIs and the potential severity of those interactions. RESULTS: A total of 9% (87 of 935) of patients who underwent DAIR or revision arthroplasty for PJI met IDSA criteria, suggesting that rifampin use would have been appropriate. Of those meeting IDSA criteria, 49% (43 of 87) started rifampin. Of those who started on rifampin for staphylococcal PJI, 19% (8 of 43) discontinued it before the planned 6-week course was complete as documented in the EMR. Among the patients who did not receive rifampin when it appeared that they ought to have based on IDSA criteria, no reason for this decision was documented in 70% (31 of 44); among those for whom a reason was documented, it was DDI in 8 of 13, concern for hepatotoxicity in 1 of 13, history of a side effect in 1 of 13, and other reasons in 3 of 13. Among the patients whose courses were terminated before the planned course was completed, it was a gastrointestinal issue in 5 of 8, acute kidney injury in 1 of 8, or other reasons in 2 of 8. CONCLUSION: Only about one-half of patients who met IDSA criteria for adjunctive rifampin therapy for staphylococcal PJI after DAIR or one-stage revision at a large tertiary referral academic center were started on treatment. For most patients who did not receive rifampin, there is no documentation for why not. Given the evidence of superior outcomes for patients treated with adjunctive rifampin, it is imperative that all patients meeting criteria be started on the medication unless there is a clear contraindication, which should be documented. Future studies should further evaluate the clinical benefit of rifampin when treating staphylococcal PJI and which DDIs would be considered true contraindications of treatment. This could be achieved with a prospective study that evaluates successful long-term infection-free survival after treatment with adjunctive rifampin while accounting for and stratifying the potential clinical risk of these DDIs. LEVEL OF EVIDENCE: Level IV, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Kugelman DN, Leal J, Shah S, et al. How Often Is Rifampin Therapy Initiated and Completed in Patients With Periprosthetic Joint Infections? Clin Orthop Relat Res. 2025. PMID: 39854165. doi:10.1097/CORR.0000000000003377

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。